Background
Methods
Tissue culture and western blotting
MYC, ATM and ATR mRNA expressions in breast cancer
MYC, ATM and ATR protein expressions in breast cancer
Tissue microarrays (TMAs) and immunohistochemistry (IHC)
Evaluation of immune staining
Statistical analysis
Results
High ATR promotes aggressive phenotypes in MYC overexpressed breast cancers
Variable | ATR and MYC protein co-expression | p value | Adjusted p value* | |||
---|---|---|---|---|---|---|
MYC−/ATR− | MYC−/ATR+ | MYC+/ATR− | MYC+/ATR+ | |||
N (%) | N (%) | N (%) | N (%) | |||
Tumour size (cm) | ||||||
≤ 2.0 | 115 (50.0) | 59 (38.1) | 110 (49.1) | 73 (39.7) |
0.03
| 0.053 |
> 2.0 | 115 (50.0) | 96 (61.9) | 114 (50.9) | 111 (60.3) | ||
Vascular invasion | ||||||
Negative | 166 (72.5) | 94 (60.6) | 152 (68.8) | 106 (57.6) |
0.005
|
0.013
|
Positive | 63 (27.5) | 61 (39.4) | 69 (31.2) | 78 (42.4) | ||
Tumour gradea | ||||||
G1 | 48 (20.9) | 18 (11.8) | 40 (17.9) | 15 (8.2) |
0.001
|
0.004
|
G2 | 78 (33.9) | 42 (27.4) | 70 (31.4) | 51 (27.9) | ||
G3 | 104 (45.2) | 93 (60.8) | 113 (50.7) | 117 (63.9) | ||
Tumour type | ||||||
Ductal (incl mixed) | 192 (83.6) | 134 (86.4) | 195 (87.1) | 169 (91.8) | 0.076 | 0.121 |
Lobular | 20 (8.7) | 15 (9.7) | 13 (5.8) | 7 (3.8) | ||
Medullary-like | 7 (3.0) | 0 (0.0) | 10 (4.5) | 6 (3.3) | ||
Miscellaneous | 1 (0.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
Special type | 10 (4.3) | 6 (3.9) | 6 (2.6) | 2 (1.1) | ||
Tubules | ||||||
1 | 14 (6.4) | 5 (3.2) | 9 (4.3) | 5 (2.7) | 0.583 | 0.717 |
2 | 75 (34.4) | 48 (31.4) | 72 (34.1) | 65 (35.5) | ||
3 | 129 (59.2) | 100 (65.4) | 130 (61.6) | 113 (61.8) | ||
Pleomorphism | ||||||
1 | 2 (0.9) | 1 (0.6) | 6 (2.9) | 1 (0.5) |
0.003
|
0.0096
|
2 | 93 (42.7) | 61 (39.9) | 78 (37.3) | 47 (25.7) | ||
3 | 123 (56.4) | 91 (59.5) | 125 (59.8) | 135 (73.8) | ||
Mitosis | ||||||
1 | 92 (42.2) | 40 (26.2) | 66 (31.3) | 38 (20.8) |
0.00012
|
0.00064
|
2 | 36 (16.5) | 21 (13.7) | 40 (18.9) | 35 (19.1) | ||
3 | 90 (41.3) | 92 (60.1) | 105 (49.8) | 110 (60.1) | ||
NPI group | ||||||
GPG | 79 (34.3) | 35 (22.6) | 71 (31.7) | 33 (17.9) | < 0.00001 | < 0.00001 |
MPG | 128 (55.7) | 83 (53.5) | 125 (55.8) | 96 (52.2) | ||
PPG | 23 (10.0) | 37 (23.9) | 28 (12.5) | 55 (29.9) | ||
ER status | ||||||
Negative | 63 (27.4) | 38 (24.5) | 58 (26.2) | 51 (27.7) | 0.908 | 0.968 |
Positive | 167 (72.6) | 117 (75.5) | 163 (73.8) | 133 (72.3) | ||
PR status | ||||||
Negative | 105 (45.9) | 64 (42.4) | 98 (44.7) | 77 (42.3) | 0.864 | 0.987 |
Positive | 124 (54.1) | 87 (57.6) | 121 (55.3) | 105 (57.7) | ||
HER2 status | ||||||
Negative | 187 (82.7) | 122 (81.3) | 194 (87.0) | 151 (82.5) | 0.437 | 0.582 |
Positive | 39 (17.3) | 28 (18.7) | 29 (13.0) | 32 (17.5) | ||
Triple negative | ||||||
Non-triple negative | 188 (82.5) | 132 (86.8) | 175 (79.5) | 144 (78.3) | 0.183 | 0.266 |
Triple negative | 40 (17.5) | 20 (13.2) | 45 (20.5) | 40 (21.7) | ||
Basal phenotype | ||||||
Negative | 175 (76.8) | 121 (78.1) | 149 (66.8) | 127 (69.0) |
0.027
| 0.054 |
Positive | 53 (23.2) | 34 (21.9) | 74 (33.2) | 57 (31.0) |
Variable | ATR and MYC mRNA co-expression | p value | Adjusted p value* | |||
---|---|---|---|---|---|---|
MYC−/ATR− | MYC−/ATR+ | MYC+/ATR− | MYC+/ATR+ | |||
N (%) | N (%) | N (%) | N (%) | |||
Tumour size (cm) | ||||||
T 1a+b(1.0) | 58 (4.5) | 24 (5.6) | 9 (4.6) | 1 (2.2) | 0.333 | 0.428 |
T 1c(> 1.0–2.0) | 527 (40.9) | 156 (36.6) | 64 (32.5) | 19 (42.2) | ||
T2 (> 2.0–5) | 648 (50.3) | 220 (51.6) | 111 (56.3) | 22 (48.9) | ||
T3 (> 5) | 56 (4.3) | 26 (6.1) | 13 (6.6) | 3 (6.7) | ||
Lymph node stage | ||||||
Negative | 686 (52.8) | 232 (54.1) | 91 (46.4) | 26 (56.5) | 0.612 | 0.718 |
Positive (1–3) | 210 (16.2) | 65 (15.2) | 34 (17.3) | 5 (10.9) | ||
Positive (> 3) | 404 (31.1) | 132 (30.8) | 71 (36.2) | 15 (32.6) | ||
Gradea | ||||||
G1 | 120 (9.7) | 37 (9.0) | 11 (5.6) | 1 (2.3) |
0.00018
|
0.00048
|
G2 | 524 (42.2) | 176 (42.9) | 57 (29.2) | 13 (30.2) | ||
G3 | 597 (48.1) | 197 (48.0) | 127 (65.1) | 29 (67.4) | ||
NPI | ||||||
≤ 3.4 | 274 (22.2) | 84 (20.7) | 25 (13.2) | 5 (11.9) |
0.016
|
0.0288
|
> 3.4 | 958 (77.8) | 322 (79.3) | 165 (86.8) | 37 (88.1) | ||
HER 2 overexpression | ||||||
No | 1119(85.9) | 382 (88.8) | 187 (94.0) | 44 (95.7) |
0.003
|
0.00675
|
Yes | 183 (14.1) | 48 (11.2) | 12 (6.0) | 2 (4.3) | ||
ER | ||||||
Negative | 270 (20.7) | 92 (21.4) | 84 (42.2) | 24 (52.2) | < 0.00001 | < 0.00001 |
Positive | 1032(79.3) | 338 (78.6) | 115 (57.8) | 22 (47.8) | ||
PR | ||||||
Negative | 597 (45.9) | 194 (45.1) | 116 (58.3) | 29 (63.0) |
0.001
|
0.00245
|
Positive | 705 (54.1) | 236 (54.9) | 83 (41.7) | 17 (37.0) | ||
Triple negative | ||||||
No | 1137(87.3) | 371 (86.3) | 126 (63.3) | 26 (56.5) | < 0.00001 | < 0.00001 |
Yes | 165 (12.7) | 59 (13.7) | 73 (36.7) | 20 (43.5) | ||
Genefu subtype | ||||||
ER−/Her-2 negative | 77 (11.5) | 30 (14.6) | 35 (32.4) | 8 (57.1) | < 0.00001 | < 0.00001 |
ER+/Her-2 negative/high proliferation | 231 (34.6) | 87 (42.4) | 45 (41.7) | 3 (21.4) | 0.083 | 0.124 |
ER+/Her-2 negative/low proliferation | 280 (42.0) | 65 (31.7) | 21 (19.4) | 2 (14.3) |
0.00001
|
0.00002
|
Her-2 positive | 79 (11.8) | 23 (11.2) | 7 (6.5) | 1 (7.1) | 0.401 | 0.492 |
PAM50 subtype | ||||||
PAM50.Her2 | 166 (14.2) | 66 (16.4) | 6 (3.7) | 0 (0.0) |
0.00005
|
0.000156
|
PAM50.Basal | 173 (14.8) | 54 (13.4) | 77 (47.0) | 26 (74.3) | < 0.00001 | < 0.00001 |
PAM50.LumA | 509 (43.5) | 166 (41.2) | 38 (23.2) | 2 (5.7) | < 0.00001 | < 0.00001 |
PAM50.LumB | 322 (27.5) | 117 (29.0) | 43 (26.2) | 7 (20.0) | 0.663 | 0.745 |
Low ATM promotes aggressive phenotypes in MYC overexpressed breast cancers
Variable | ATM and MYC protein co-expression | p value | Adjusted p value* | |||
---|---|---|---|---|---|---|
MYC−/ATM− | MYC−/ATM+ | MYC+/ATM− | MYC+/ATM+ | |||
N (%) | N (%) | N (%) | N (%) | |||
Tumour size (cm) | ||||||
≤ 2.0 | 93 (45.8) | 77 (54.2) | 66 (41.0) | 96 (50.5) | 0.101 | 1.616 |
> 2.0 | 110 (54.2) | 65 (45.8) | 95 (59.0) | 94 (49.5) | ||
Vascular invasion | ||||||
Negative | 127 (62.9) | 112 (78.9) | 103 (64.0) | 129 (68.3) |
0.01
|
0.013
|
Positive | 75 (37.1) | 30 (21.1) | 58 (36.0) | 60 (31.7) | ||
Tumour gradea | ||||||
G1 | 23 (11.3) | 39 (27.2) | 9 (5.6) | 41 (21.7) | < 0.00001 | < 0.00001 |
G2 | 61 (30.0) | 54 (37.8) | 48 (29.8) | 60 (31.7) | ||
G3 | 119 (58.6) | 50 (35.0) | 104 (64.6) | 88 (46.6) | ||
Tumour type | ||||||
Ductal (incl mixed) | 172 (84.7) | 117 (82.4) | 140 (87.0) | 169 (89.0) |
0.023
|
0.028
|
Lobular | 17 (8.5) | 18 (12.7) | 10 (6.2) | 9 (4.7) | ||
Medullary-like | 7 (3.4) | 0 (0.0) | 9 (5.6) | 8 (4.2) | ||
Special type | 7 (3.4) | 7 (4.9) | 2 (1.2) | 4 (2.1) | ||
Tubules | ||||||
1 | 9 (4.5) | 10 (7.1) | 5 (3.1) | 6 (3.2) |
0.00016
|
0.00028
|
2 | 49 (24.6) | 57 (40.7) | 45 (28.7) | 83 (44.9) | ||
3 | 141 (70.9) | 73 (52.2) | 107 (68.2) | 96 (51.9) | ||
Pleomorphism | ||||||
1 | 4 (2.0) | 4 (2.8) | 1 (0.7) | 6 (3.3) |
0.00007
|
0.00015
|
2 | 69 (34.7) | 74 (52.9) | 41 (26.1) | 73 (39.9) | ||
3 | 126 (66.3) | 62 (44.3) | 115 (73.2) | 104 (56.8) | ||
Mitosis | ||||||
1 | 58 (29.1) | 75 (53.6) | 29 (18.5) | 62 (33.5) | < 0.00001 | < 0.00001 |
2 | 35 (17.6) | 17 (12.1) | 28 (17.8) | 42 (22.7) | ||
3 | 106 (53.3) | 48 (34.3) | 100 (63.7) | 81 (43.8) | ||
NPI group | ||||||
GPG | 48 (23.7) | 59 (41.6) | 28 (17.4) | 65 (34.2) | < 0.00001 |
0.00001
|
MPG | 118 (58.1) | 76 (53.5) | 97 (60.2) | 100 (52.6) | ||
PPG | 37 (18.2) | 7 (4.9) | 36 (22.4) | 25 (13.2) | ||
ER status | ||||||
Negative | 69 (33.8) | 23 (16.1) | 59 (36.6) | 40 (21.1) |
0.00002
|
0.00007
|
Positive | 135 (66.2) | 120 (83.9) | 102 (63.4) | 150 (78.9) | ||
PR status | ||||||
Negative | 100 (49.8) | 41 (29.1) | 83 (51.6) | 65 (34.4) |
0.00001
|
0.00006
|
Positive | 101 (50.2) | 100 (70.9) | 78 (48.4) | 124 (65.6) | ||
HER2 status | ||||||
Negative | 163 (81.5) | 127 (91.4) | 136 (85.0) | 158 (83.2) | 0.081 | 0.086 |
Positive | 37 (18.5) | 12 (8.6) | 24 (15.0) | 32 (16.8) | ||
Triple negative | ||||||
Non-triple negative | 159 (79.1) | 124 (87.3) | 112 (69.6) | 165 (86.8) |
0.00007
|
0.00015
|
Triple negative | 42 (20.9) | 18 (12.7) | 49 (30.4) | 25(13.2) | ||
Basal phenotype | ||||||
Negative | 160 (79.6) | 110 (78.6) | 107 (66.5) | 131 (68.9) |
0.008
|
0.0116
|
Positive | 41 (20.3) | 30 (21.4) | 54 (33.5) | 59 (30.1) |
Variable | ATM and MYC mRNA co-expression | p value | Adjusted p value* | |||
---|---|---|---|---|---|---|
MYC−/ATM− | MYC−/ATM+ | MYC+/ATM− | MYC+/ATM+ | |||
N (%) | N (%) | N (%) | N (%) | |||
Tumour size (cm) | ||||||
T 1a+b(1.0) | 6 (3.3) | 76 (5.0) | 3 (16.7) | 7 (3.1) |
0.00038
|
0.0009
|
T 1c(> 1.0–2.0) | 72 (39.3) | 611 (39.9) | 2 (11.1) | 81 (36.2) | ||
T2 (> 2.0–5) | 89 (48.6) | 779 (50.8) | 9 (50.0) | 124 (55.4) | ||
T3 (> 5) | 16 (8.7) | 66 (4.3) | 4 (22.2) | 12 (5.4) | ||
Lymph node stage | ||||||
Negative | 98 (53.0) | 820 (53.1) | 9 (50.0) | 108 (48.2) | 0.803 | |
Positive (1–3) | 32 (17.3) | 243 (15.7) | 2 (11.1) | 37 (16.5) | ||
Positive (> 3) | 55 (29.7) | 481 (31.2) | 7 (38.9) | 79 (35.3) | ||
Gradea | ||||||
G1 | 20 (11.2) | 137 (9.3) | 0 (0.0) | 12 (5.4) |
0.00006
|
0.0002
|
G2 | 73 (40.8) | 627 (4.6) | 8 (47.1) | 62 (28.1) | ||
G3 | 86 (48.0) | 708 (48.1) | 9 (52.9) | 147 (66.5) | ||
NPI | ||||||
≤ 3.4 | 36 (20.3) | 322 (22.0) | 3 (17.6) | 27 (12.6) |
0.016
|
0.0288
|
> 3.4 | 141 (79.7) | 1139 (78.0) | 14 (82.4) | 188 (87.4) | ||
HER 2 overexpression | ||||||
No | 157 (84.9) | 1344 (86.9) | 17 (94.4) | 214 (94.3) |
0.007
|
0.01
|
Yes | 28 (15.1) | 203 (13.1) | 1 (5.6) | 13 (5.7) | ||
ER | ||||||
Negative | 39 (21.1) | 323 (20.9) | 6 (33.3) | 102 (44.9) | < 0.00001 | < 0.00001 |
Positive | 146 (78.9) | 1224 (79.1) | 12 (66.7) | 125 (55.1) | ||
PR | ||||||
Negative | 76 (41.1) | 715 (46.2) | 14 (77.8) | 131 (57.7) |
0.00016
|
0.0004
|
Positive | 109 (58.9) | 832 (53.8) | 4 (22.2) | 96 (42.3) | ||
Triple negative | ||||||
No | 162 (87.6) | 1346 (87.0) | 13 (72.2) | 139 (61.2) | < 0.00001 | < 0.00001 |
Yes | 23 (12.4) | 201 (13.0) | 5 (27.8) | 88 (38.8) | ||
Genefu subtype | ||||||
ER−/Her-2 negative | 12 (12.9) | 95 (12.2) | 2 (25.0) | 41 (36.0) | < 0.00001 | < 0.00001 |
ER+/Her-2 negative/high proliferation | 33 (35.5) | 285 (36.6) | 3 (37.5) | 45 (39.5) | 0.933 | 25.191 |
ER+/Her-2 negative/low proliferation | 34 (36.6) | 311 (39.9) | 2 (25.0) | 21 (18.4) |
0.00015
|
0.0004
|
Her-2 positive | 14 (15.1) | 88 (11.3) | 1 (12.5) | 7 (6.1) | 0.224 | 0.288 |
PAM50 subtype | ||||||
PAM50.Her2 | 31 (18.3) | 201 (14.3) | 1 (7.1) | 5 (2.7) |
0.00004
|
0.0001
|
PAM50.Basal | 23 (13.6) | 204 (14.5) | 6 (42.9) | 97 (52.4) | < 0.00001 | < 0.00001 |
PAM50.LumA | 67 (39.6) | 608 (43.3) | 2 (14.3) | 38 (20.5) | < 0.00001 | < 0.00001 |
PAM50.LumB | 48 (28.4) | 391 (27.8) | 5 (35.7) | 45 (24.3) | 0.67 | 0.7865 |